Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POET-IRON
NCT07523646Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Inorganic Nanoparticles, Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
A Phase 4 trial of ferric derisomaltose, darbepoetin alfa in anemia, sponsored by Rigshospitalet. Started May 2026; status: recruiting.
02
Drugs
ferric derisomaltosedarbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT07523646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523646.